BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:U.S. CDMRP – Peer Reviewed Cancer Research Program | Research Fu
 nding
DTSTART;VALUE=DATE:20260626
DTSTAMP:20260528T052302Z
UID:0371056b8c6b9d172e22cab59bb0d8afbf8a3805735717b0e3aef8c3
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the 2026 Peer Revie
 wed Cancer Research Program (PRCRP). Several award programs are available:
 \n\n	The Idea Award supports innovative\, untested\, high-risk/potentially
  high-reward concepts\, theories\, paradigms\, and/or basic cancer researc
 h. The advancement of knowledge in cancer research\, patient care\, and/or
  treatment options in the Military Health System (MHS) is critical to acti
 ve-duty Service Members\, Veterans\, other military beneficiaries\, and th
 e American public.\n	The Impact Award supports mature research that will h
 ave a near-term impact on clinical cancer care in one of the Topic Areas. 
 Applicants must consider how the research project will lead to the advance
 ment of knowledge in cancer research\, patient care and/or treatment optio
 ns in the MHS.\n	The Clinical Trial Award supports the rapid implementatio
 n of clinical trials with the potential to have a significant impact on th
 e treatment or management of cancer within at least one of the Topic Areas
 . Clinical trials proposed may evaluate promising new products\, pharmacol
 ogic agents (drugs or biologics)\, devices\, clinical guidance\, and/or em
 erging approaches and technologies. Proposed projects may range from small
  proof-of-concept trials (e.g.\, pilot\, first-in-human\, phase 0) that ev
 aluate the effects of interventions or inform the design of more advanced 
 trials to large-scale trials (up to phase III) to determine efficacy in re
 levant patient populations.\n\nAll applications must specifically address 
 at least one of the Topic Areas. The FY26 PRCRP Topic Areas are listed at 
 the end of this announcement.\n\nFunding:      \nIdea Award: max. $60
 0K\nImpact Award: $1.5M-$2M\nClinical Trial Award: max. $4.5M\nNote: Cost 
 caps are total costs (direct plus indirect costs). In accordance with EP
 FL guidelines\, budgets should include a 20% overhead\, and the total budg
 et must remain within the grant’s maximum allowable funding\n\n\nDuratio
 n:     \nIdea Award: 2 years\nImpact Award: 3 years\nClinical Trial Aw
 ard: 4 years\n\nEligibility: Applicants from international organizations o
 r institutions are eligible to apply\, and there are no citizenship restri
 ctions. Independent investigators at all career levels are eligible.\n\nHo
 w to Apply: Pre-applications are submitted through the eBRAP platform. The
 y should contain contact information\, a letter of intent\, and a list of 
 collaborators and key personnel as suggested on the platform. Full applica
 tions will be made via a Grants.gov workspace.\n\nPre-Application Deadline
 : 26 June 2026\, 5:00 p.m. Eastern time\nFull Application Deadline: 05 Oct
 ober 2026\, 11:59 p.m Eastern Time\n                         
                                   \nFurther information:\
 n\n\n	To find the full program announcements and to start your pre-applica
 tion see here\n	A useful summary of each call can be found here\n	For ques
 tions about the eBRAP or Grants.gov platforms\, contact the Research Offic
 e.\n	Grants.gov Funding Opportunity Numbers:\n	\n		Idea Award: HT942526PRC
 RPIA\n		Impact Award: HT942526PRCRPIPA\n		Clinical Trial Award: HT942526PR
 CRPCTA\n	\n	\n\nFY26 PRCRP Topic Areas:\nBladder cancer • Blood cancers 
 • Brain cancer • Colorectal cancer • Endometrial cancer • Esophage
 al cancer • Germ cell cancers • Glioblastoma • Liver cancer • Lymp
 homa • Mesothelioma • Metastatic cancers • Myeloma • Neuroblastoma
  • Neuroendocrine Tumors • Pediatric\, adolescent\, and young adult ca
 ncers1 • Pediatric brain tumors • Sarcoma • Stomach cancer • Thyro
 id cancer\n 
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR